Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ATM | Q13315 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6483806 | 0.78 | AHR (0.41) | KDM4E | |
| SCHEMBL17127163 | 0.73 | NPC1 (0.37) | PDE4DKDM4EL3MBTL1MEN1KMT2A | |
| SCHEMBL6482791 | 0.73 | KDM4E (0.42) | KDM4EL3MBTL1MEN1KMT2AATM | |
| SCHEMBL13509561 | 0.71 | NPC1 (0.41) | PDE4DKDM4EL3MBTL1MEN1KMT2A | |
| SCHEMBL15695201 | 0.67 | MAP4K4 (0.46) | KDM4EL3MBTL1MEN1KMT2AHPGD | |
| SCHEMBL15855202 | 0.67 | PLA2G2A (0.42) | PDE4DKDM4EL3MBTL1MEN1KMT2A | |
| SCHEMBL15855200 | 0.67 | PLA2G2A (0.42) | PDE4DKDM4EL3MBTL1MEN1KMT2A | |
| SCHEMBL15317426 | 0.67 | PLA2G2A (0.42) | PDE4DKDM4EL3MBTL1MEN1KMT2A | |
| SCHEMBL16482063 | 0.66 | NPC1 (0.44) | PDE4DKDM4EL3MBTL1MEN1KMT2A | |
| SCHEMBL15835963 | 0.66 | NPC1 (0.44) | PDE4DKDM4EL3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075332-A1 | Tricyclic compounds with antiviral activity | WARNER LAMBERT COMPANY | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075332-A1 | Tricyclic compounds with antiviral activity | HDAC8, CDK8, ZC3HAV1 | PDE4D 4599/4885KDM4E 1476/4885L3MBTL1 2831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.